Rezolute Inc is trading at $4.34 (5.1% down), easing after a multi-day rally driven by positive interim Phase 3 upLIFT data for ersodetug in tumor hyperinsulinism.
- The stock appears to be consolidating following sharp gains of 10–15% earlier this week.
- No new negative company-specific developments have been reported today, with broader markets trading mixed.